• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Asymptomatic SARS-CoV-2 infection in two patients with multiple sclerosis treated with fingolimod.两名接受芬戈莫德治疗的多发性硬化症患者出现无症状的严重急性呼吸综合征冠状病毒2感染。
Mult Scler Relat Disord. 2020 Oct;45:102414. doi: 10.1016/j.msard.2020.102414. Epub 2020 Jul 19.
2
COVID-19 infection in a patient with multiple sclerosis treated with fingolimod.一名接受芬戈莫德治疗的多发性硬化症患者感染了新冠病毒。
Neurol Neuroimmunol Neuroinflamm. 2020 May 5;7(4). doi: 10.1212/NXI.0000000000000753. Print 2020 Jul.
3
Patients with MS treated with immunosuppressive agents: Across the COVID-19 spectrum.接受免疫抑制剂治疗的多发性硬化症患者：在整个新冠疫情范围内。
Rev Neurol (Paris). 2020 Jun;176(6):523-525. doi: 10.1016/j.neurol.2020.04.009. Epub 2020 Apr 27.
4
The multiple sclerosis (MS) drugs as a potential treatment of ARDS in COVID-19 patients.多发性硬化症（MS）药物可能成为 COVID-19 患者中急性呼吸窘迫综合征（ARDS）的一种治疗方法。
Mult Scler Relat Disord. 2020 Oct;45:102437. doi: 10.1016/j.msard.2020.102437. Epub 2020 Jul 31.
5
A fine balance: Immunosuppression and immunotherapy in a patient with multiple sclerosis and COVID-19.微妙的平衡：免疫抑制与免疫疗法在多发性硬化合并 COVID-19 患者中的应用。
Mult Scler Relat Disord. 2020 Jul;42:102182. doi: 10.1016/j.msard.2020.102182. Epub 2020 May 8.
6
Immunologic characterization of a immunosuppressed multiple sclerosis patient that recovered from SARS-CoV-2 infection.免疫抑制多发性硬化症患者从 SARS-CoV-2 感染中康复后的免疫特征。
J Neuroimmunol. 2020 Aug 15;345:577282. doi: 10.1016/j.jneuroim.2020.577282. Epub 2020 May 29.
7
Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod.多发性硬化症患者在接受芬戈莫德治疗后感染严重 COVID-19。
Mult Scler Relat Disord. 2020 Jul;42:102180. doi: 10.1016/j.msard.2020.102180. Epub 2020 May 6.
8
SARS-CoV-2 and Multiple Sclerosis: Not All Immune Depleting DMTs are Equal or Bad.严重急性呼吸综合征冠状病毒2与多发性硬化症：并非所有免疫耗竭性疾病修正治疗药物都是相同的或有害的。
Ann Neurol. 2020 Jun;87(6):794-797. doi: 10.1002/ana.25770.
9
COVID-19 in teriflunomide-treated patients with multiple sclerosis.新冠肺炎在多发性硬化症接受特立氟胺治疗的患者中。
J Neurol. 2020 Oct;267(10):2790-2796. doi: 10.1007/s00415-020-09944-8. Epub 2020 Jun 3.
10
Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide.用芬戈莫德和特立氟胺治疗的多发性硬化症患者中新冠病毒血清转化及病情进展缓慢情况
J Neurol Sci. 2020 Sep 15;416:117011. doi: 10.1016/j.jns.2020.117011. Epub 2020 Jul 4.

引用本文的文献

1
An update on the use of sphingosine 1-phosphate receptor modulators for the treatment of relapsing multiple sclerosis.鞘氨醇 1-磷酸受体调节剂在治疗复发性多发性硬化症中的应用进展。
Expert Opin Pharmacother. 2023 Mar;24(4):495-509. doi: 10.1080/14656566.2023.2178898. Epub 2023 Mar 22.
2
PET Study of Sphingosine-1-phosphate Receptor 1 Expression in Response to Infection.PET 研究神经鞘氨醇-1-磷酸受体 1 表达对感染的反应。
Mol Imaging. 2021 Oct 4;2021:9982020. doi: 10.1155/2021/9982020. eCollection 2021.
3
Potential role of marine species-derived bioactive agents in the management of SARS-CoV-2 infection.海洋物种来源的生物活性物质在管理 SARS-CoV-2 感染中的潜在作用。
Future Microbiol. 2021 Nov;16(16):1289-1301. doi: 10.2217/fmb-2021-0024. Epub 2021 Oct 25.
4
Multiple Sclerosis, Disease-Modifying Therapies and COVID-19: A Systematic Review on Immune Response and Vaccination Recommendations.多发性硬化症、疾病修正疗法与2019冠状病毒病：关于免疫反应和疫苗接种建议的系统综述
Vaccines (Basel). 2021 Jul 11;9(7):773. doi: 10.3390/vaccines9070773.
5
Emerging COVID-19 Neurological Manifestations: Present Outlook and Potential Neurological Challenges in COVID-19 Pandemic.新型冠状病毒肺炎相关神经系统表现：目前的认识及新冠大流行期间的潜在神经学挑战。
Mol Neurobiol. 2021 Sep;58(9):4694-4715. doi: 10.1007/s12035-021-02450-6. Epub 2021 Jun 24.
6
New perspective towards therapeutic regimen against SARS-CoV-2 infection.针对 SARS-CoV-2 感染的治疗方案的新视角。
J Infect Public Health. 2021 Jul;14(7):852-862. doi: 10.1016/j.jiph.2021.05.009. Epub 2021 May 26.
7
An Overview of the Efficacy and Safety of Ozanimod for the Treatment of Relapsing Multiple Sclerosis.奥扎莫德治疗复发型多发性硬化症的疗效和安全性概述。
Drug Des Devel Ther. 2021 May 11;15:1993-2004. doi: 10.2147/DDDT.S240861. eCollection 2021.
8
Post-infectious inflammatory syndrome associated with SARS-CoV-2 in a paediatric patient with Down syndrome.儿童唐氏综合征患者感染 SARS-CoV-2 后并发炎症综合征。
BMJ Case Rep. 2021 Apr 15;14(4):e240490. doi: 10.1136/bcr-2020-240490.
9
COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system: A systematic review.COVID-19 与中枢神经系统脱髓鞘疾病患者的疾病修正治疗：系统评价。
Mult Scler Relat Disord. 2021 May;50:102800. doi: 10.1016/j.msard.2021.102800. Epub 2021 Jan 29.
10
Coronavirus disease 2019 and neurodegenerative disease: what will the future bring?新型冠状病毒病 2019 与神经退行性疾病：未来将会怎样？
Curr Opin Psychiatry. 2021 Mar 1;34(2):177-185. doi: 10.1097/YCO.0000000000000688.

本文引用的文献

1
Prevalence of Asymptomatic SARS-CoV-2 Infection.无症状严重急性呼吸综合征冠状病毒2感染的患病率
Ann Intern Med. 2021 Feb;174(2):286-287. doi: 10.7326/L20-1285.
2
Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission.全球 COVID-19 荟萃分析显示，男性性别是死亡和 ICU 入院的风险因素。
Nat Commun. 2020 Dec 9;11(1):6317. doi: 10.1038/s41467-020-19741-6.
3
Asymptomatic patients as a source of COVID-19 infections: A systematic review and meta-analysis.无症状患者作为新冠病毒感染源：一项系统综述与荟萃分析
Int J Infect Dis. 2020 Sep;98:180-186. doi: 10.1016/j.ijid.2020.06.052. Epub 2020 Jun 17.
4
Immunologic characterization of a immunosuppressed multiple sclerosis patient that recovered from SARS-CoV-2 infection.免疫抑制多发性硬化症患者从 SARS-CoV-2 感染中康复后的免疫特征。
J Neuroimmunol. 2020 Aug 15;345:577282. doi: 10.1016/j.jneuroim.2020.577282. Epub 2020 May 29.
5
COVID-19 in MS: Initial observations from the Pacific Northwest.多发性硬化症中的新冠病毒病：来自美国太平洋西北地区的初步观察
Neurol Neuroimmunol Neuroinflamm. 2020 May 26;7(5). doi: 10.1212/NXI.0000000000000783. Print 2020 Sep 3.
6
Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod.多发性硬化症患者在接受芬戈莫德治疗后感染严重 COVID-19。
Mult Scler Relat Disord. 2020 Jul;42:102180. doi: 10.1016/j.msard.2020.102180. Epub 2020 May 6.
7
SARS-CoV-2 and Multiple Sclerosis: Not All Immune Depleting DMTs are Equal or Bad.严重急性呼吸综合征冠状病毒2与多发性硬化症：并非所有免疫耗竭性疾病修正治疗药物都是相同的或有害的。
Ann Neurol. 2020 Jun;87(6):794-797. doi: 10.1002/ana.25770.
8
COVID-19 infection in a patient with multiple sclerosis treated with fingolimod.一名接受芬戈莫德治疗的多发性硬化症患者感染了新冠病毒。
Neurol Neuroimmunol Neuroinflamm. 2020 May 5;7(4). doi: 10.1212/NXI.0000000000000753. Print 2020 Jul.
9
Sex-specific clinical characteristics and prognosis of coronavirus disease-19 infection in Wuhan, China: A retrospective study of 168 severe patients.性别特异性临床特征和新型冠状病毒感染的预后：中国武汉 168 例重症患者的回顾性研究。
PLoS Pathog. 2020 Apr 28;16(4):e1008520. doi: 10.1371/journal.ppat.1008520. eCollection 2020 Apr.
10
The COVID-19 pandemic and the use of MS disease-modifying therapies.新冠疫情与多发性硬化症疾病修正疗法的使用
Mult Scler Relat Disord. 2020 Apr;39:102073. doi: 10.1016/j.msard.2020.102073. Epub 2020 Mar 27.

Asymptomatic SARS-CoV-2 infection in two patients with multiple sclerosis treated with fingolimod.

作者信息

Mallucci Giulia, Zito Antonio, Fabbro Beatrice Dal, Bergamaschi Roberto

机构信息

Multiple Sclerosis Centre, IRCCS Mondino Foundation, via Mondino 2, 27100, Pavia, Italy; Department of Brain and Behavioural Sciences, University of Pavia, Pavia, Italy.

Multiple Sclerosis Centre, IRCCS Mondino Foundation, via Mondino 2, 27100, Pavia, Italy.

出版信息

Mult Scler Relat Disord. 2020 Oct;45:102414. doi: 10.1016/j.msard.2020.102414. Epub 2020 Jul 19.

DOI:10.1016/j.msard.2020.102414
PMID:32711296
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7369008/
Abstract
摘要